Exenatide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Also: AM833, NN9838
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Key Comparison Insights
- Exenatide is FDA approved, while Cagrilintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Cagrilintide (Human Trials).
Detailed Comparison
| Attribute | Exenatide | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite. | Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness. |
| Common Dosing | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection | Subcutaneous injection once weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use expected |
| Best Time to Take | Before bed or morning (fasted) | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels. | REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication. |
Frequently Asked Questions: Exenatide vs Cagrilintide
What is the difference between Exenatide and Cagrilintide?
Exenatide is a weight loss peptide that the first glp-1 receptor agonist approved for diabetes. derived from gila monster saliva. available in twice-daily and weekly formulations. Cagrilintide is a weight loss peptide that a long-acting amylin analog developed by novo nordisk for obesity treatment. works through a different mechanism than glp-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. shows enhanced weight loss when combined with semaglutide (cagrisema). The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Exenatide and Cagrilintide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.